Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2020 | OPTIPARK trial: opicapone in clinical practice

Georg Ebersbach • 27 May 2020
EAN 2020
Movement Disorders Parkinson's Disease Levodopa Opicapone
OPTIPARK

Georg Ebersbach, MD, Movement Disorders Clinic, Beelitz‐Heilstätten, Germany, discusses the OPTIPARK trial (NCT02847442), a prospective, open-label, uncontrolled, single-group, multi-center trial in Parkinson’s disease patients with wearing-off motor fluctuations. In the study, patients with Parkinson’s disease and motor fluctuations were treated with opicapone for 3 or 6 months in addition to their current levodopa and other antiparkinsonian treatments. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).

More from Georg Ebersbach

Future treatment directions for Parkinson's disease
2:40
Future treatment directions for Parkinson's disease
Georg Ebersbach • 27 May 2020
Parkinson's disease: physiotherapy, speech and occupational therapy
2:07
Parkinson's disease: physiotherapy, speech and occupational therapy
Georg Ebersbach • 27 May 2020
Opicapone in PD with motor fluctuations: post-hoc analysis of BIPARK-I and II
5:47
Opicapone in PD with motor fluctuations: post-hoc analysis of BIPARK-I and II
Georg Ebersbach • 27 May 2020

Related Videos

Current treatment and unmet needs in neurologic Wilson's disease
3:15
Current treatment and unmet needs in neurologic Wilson's disease
Aurelia Poujois • 29 Jun 2026
Emerging therapies for neurologic Wilson's disease
2:42
Emerging therapies for neurologic Wilson's disease
Aurelia Poujois • 29 Jun 2026
Findings from the Phase III FoCus trial: tiomolibdate choline for neurologic Wilson's disease
3:18
Findings from the Phase III FoCus trial: tiomolibdate choline for neurologic Wilson's disease
Aurelia Poujois • 29 Jun 2026
Indicators of advanced-stage Parkinson’s disease
2:30
Indicators of advanced-stage Parkinson’s disease
K. Ray Chaudhuri • 30 Jun 2026

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJNeurology is intended for healthcare professionals